1596360-47-2

Upstream product

• 1596360-12-1 5-bromo-4-methylamino-pyrimidine-2-carbonitrile 
• 1596360-16-5 methyl 6-(bromomethyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-2-carboxylate 
• 1384428-11-8 4-(2,4-dioxoimidazolidin-1-yl)benzenesulfonamide 
• 1523354-68-8 methyl 5-bromo-4-methylamino-pyrimidine-2-carboxylate 
• 1596360-15-4 methyl 6-(hydroxymethyl)-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxylate 
• 1596360-14-3 methyl 7-methyl-6-(tetrahydropyran-2-yloxymethyl)pyrrolo[2,3-d]pyrimidine-2-carboxylate 
• 1596360-13-2 methyl 4-methylamino-5-(3-tetrahydropyran-2-yloxyprop-1-ynyl)pyrimidine-2-carboxylate 

Downstream Products

• 1596360-67-6 9H-fluoren-9-ylmethyl N-[(5S)-5-cyano-5-[[6-[[2,5-dioxo-3-(4-sulfamoylphenyl)imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carbonyl]amino]pentyl]carbamate 
• 1596360-24-5 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[2,5-dioxo-3-(4-sulfamoylphenyl)imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 

Relevant academic research and scientific papers

Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is